IDP-123 Lotion

DRUG5 trials

Sponsors

Valeant Pharmaceuticals, Bausch Health Americas, Inc.

Conditions

AcneAcne Vulgaris

Phase 1

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

CompletedNCT02849873

Bausch Health Americas, Inc.Acne

Start: 2016-06-30End: 2017-01-31Updated: 2018-07-19

Phase 2

Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris

Valeant PharmaceuticalsAcne Vulgaris

Start: 2015-09-30End: 2016-06-30Target: 210Updated: 2015-09-14

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

CompletedNCT02938494

Bausch Health Americas, Inc.Acne Vulgaris

Start: 2015-11-30End: 2016-09-30Updated: 2020-09-23

Phase 3

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

CompletedNCT03168334

Bausch Health Americas, Inc.Acne Vulgaris

Start: 2017-07-11End: 2018-07-24Updated: 2021-04-01

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

CompletedNCT03168321

Bausch Health Americas, Inc.Acne Vulgaris

Start: 2017-06-29End: 2018-06-07Updated: 2021-04-01

Related Papers

Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin.

2023-12-012 citations

Safety of Tazarotene 0.045% Lotion and Hyperpigmentation Improvements in Black Participants With Moderate-to-Severe Acne

SKIN The Journal of Cutaneous Medicine2023-07-171 citations

Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.

2022-10-01

Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients.

2022-07-14

Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials.

2021-08-302 citations

Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex.

2021-06-012 citations

Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne.

2020-11-013 citations

Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex

Journal of Drugs in Dermatology2020-07-016 citations

Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity

Journal of Drugs in Dermatology2020-06-0110 citations